Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: Model based analysis

BMJ (Online)

Volumn 339, Issue 7724, 2009, Pages 787-791

  Rose, Johnie ^a   Hawthorn, Rachael L ^a   Watts, Brook ^b   Singer, Mendel E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; LIVE VACCINE; ROTAVIRUS VACCINE;

AGE; ARTICLE; BUDGET; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; FOLLOW UP; GASTROENTERITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN ROTAVIRUS; INCIDENCE; INDIA; INFECTION RISK; MASS IMMUNIZATION; MORBIDITY; MORTALITY; OUTPATIENT; OUTPATIENT CARE; PRIORITY JOURNAL; PROBABILITY; REINFECTION; STATISTICAL MODEL; VIRUS INFECTION;

CHILD; COST-BENEFIT ANALYSIS; DRUG COSTS; GASTROENTERITIS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; INCIDENCE; INDIA; MARKOV CHAINS; MASS VACCINATION; RECURRENCE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 70349650016     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b3653     Document Type: Article

References (80)

1. De Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ 1985;63:569-583 (Pubitemid 16237127)
2. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-1028 (Pubitemid 26338732)
3. Linhares AC, Gabbay YB, Freitas RB, da Rosa ES, Mascarenhas JD, Loureiro EC. Longitudinal study of rotavirus infections among children from Belem, Brazil. Epidemiol Infect 1989;102:129-145
4. Rodriguez WJ, Kim HW, Brandt CD, Schwartz RH, Gardner MK, Jeffries B, et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 1987;6:170-176
5. Simhon A, Mata L, Vives M, Rivera L, Vargas S, Ramirez G, et al. Low endemicity and low pathogenicity of rotaviruses among rural children in Costa Rica. J Infect Dis 1985;152:1134-1142 (Pubitemid 16215588)
6. Black RE, Lopez de Romana G, Brown KH, Bravo N, Bazalar OG, Kanashiro HC. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. Am J Epidemiol 1989;129:785-799 (Pubitemid 19094256)
7. Zaki AM, DuPont HL, el Alamy MA, Arafat RR, Amin K, Awad MM, et al. The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. Am J Trop Med Hyg 1986;35:1013-1022
8. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-572
9. Mrukowicz J, Szajewska H, Vesikari T. Options for the prevention of rotavirus disease other than vaccination. J Pediatr Gastroenterol Nutr 2008;46(suppl 2):S32-7. (Pubitemid 351644168)
10. WHO. Estimated rotavirus deaths for children under 5 years of age: 2004. Geneva: WHO, 2009. www.who.int/immunization-monitoring/burden/rotavirus- estimates/en/index.html.
11. Bahl R, Ray P, Subodh S, Shambharkar P, Saxena M, Parashar U, et al. Incidence of severe rotavirus diarrhea in New Delhi, India, and G and P types of the infecting rotavirus strains. J Infect Dis 2005;192(suppl 1):S114-9. (Pubitemid 41193112)
12. Diarrhoea treatment guidelines including new recommendations for the use of ORS and zinc supplementation for clinic-based healthcare workers. Washington: USAID Micronutrient Program, 2005. http://whqlibdoc.who.int/publications/2005/ a85500.pdf.
13. Dennehy PH. Rotavirus vaccines - an update. Vaccine 2007;25:3137-3141
14. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005;192(suppl 1):S160-6. (Pubitemid 41193117)
15. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalenthuman-bovine (WC3) reassortant rotavirus vaccine.N Engl J Med 2006;354:23-33.
16. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. (Pubitemid 43048947)
17. Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol 2007;5:529-539 (Pubitemid 46925381)
18. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757-1763 (Pubitemid 350137490)
19. Glass R, Parashar U, Bresee J, Turcios R, Fischer T, Widdowson M, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006;368:323-332 (Pubitemid 44067224)
20. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005;15:29-56. (Pubitemid 40070041)
21. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005;192(suppl 1):S146-59. (Pubitemid 41193116)
22. Naghipour M, Nakagomi T, Nakagomi O. Issues with reducing the rotavirus-associated mortality by vaccination in developing countries. Vaccine 2008;26:3236-3241
23. WHO. Rotavirus vaccination. Wkly Epidemiol Rec 2009;84:213-236
24. Parashar UD, Glass RI. Public health. Progress toward rotavirus vaccines. Science 2006;312:851-852
25. PATH. Proceedings of the 7th international symposium on rotavirus and rotavirus vaccines June 12-13. 2006. Lisbon, Portugal: Albert B Sabin Vaccine Institute, 2006. www.path.org/vaccineresources/files/Rotavirus-symposium- proceedings-Lisbon2006.pdf.
26. WHO. Rotavirus vaccines. Wkly Epidemiol Rec 2007;82:285-295
27. Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005;192:1720-1726 (Pubitemid 41587821)
28. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005;192(suppl 1):S133-45. (Pubitemid 41193115)
29. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007;25:373-380 (Pubitemid 44856079)
30. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009;9:29.
31. WHO. Immunization profile - India. Geneva:WHO, 2008. www.who.int/ immunization-monitoring/en/globalsummary/countryprofileresult.cfm.
32. Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008 Sep 8.
33. Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009;27:1333-1339
34. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22:259-267
35. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2009;58:1-25.
36. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008;21:198-208.
37. Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, Aaby P, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, West Africa. J Infect Dis 2002;186:593-597 (Pubitemid 34925530)
38. Banerjee I, Ramani S, Primrose B, Moses P, Iturriza-Gomara M, Gray JJ, et al. Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol 2006;44:2468-2474 (Pubitemid 44092413)
39. WHO. Life tables for WHO member states. Geneva:WHO, 2006. http://apps.who.int/whosis/database/life-tables/life-tables.cfm
40. Rose J, Singer ME. Projecting vaccine efficacy: accounting for geographic strain variations. Pharmacoeconomics 2008;26:185-189 (Pubitemid 351271378)
41. De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R, et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes. Ped Infect Dis J 2009;28:261-266
42. Sharma S, Ray P, Gentsch JR, Glass RI, Kalra V, Bhan MK. Emergence of G12 rotavirus strains in Delhi, India, in 2000 to 2007. J Clin Microbiol 2008;46:1343-1348
43. Samajdar S, Ghosh S, Chawla-Sarkar M, Mitra U, Dutta P, Kobayashi N, et al. Increase in prevalence of human group A rotavirus G9 strains as an important VP7 genotype among children in eastern India. J Clin Virol 2008;43:334-339
44. Lopez P, Linhares A, Perez-Schael I, Ruiz-Palacios G, Costa Clemens S, Sanchez N, et al. Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of the European Society of Infectious Diseases; 2006 May 3-5. Basel, Switzerland: 2006.
45. Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008;371:1181-1189
46. Global Advisory Committee on Vaccine Safety, 17-18 December 2008. Wkly Epidemiol Rec 2009;84:37-40.
47. Mendelsohn AS, Asirvatham JR, Mkaya Mwamburi D, Sowmynarayanan TV, Malik V, Muliyil J, et al. Estimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore, India. Trop Med Int Health 2008;13:934-942
48. Jain V, Parashar UD, Glass RI, Bhan MK. Epidemiology of rotavirus in India. Indian J Pediatr 2001;68:855-862
49. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007;21:205-216 (Pubitemid 47147596)
50. WHO. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the costs of rotavirus diarrhoea. Geneva: WHO, 2005. www.who.int/vaccine-research/documents/Eco-Burden-Diarrhoeal.pdf.
51. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008;8:103.
52. WHO. National burden of disease studies: a practical guide. Geneva: WHO, 2001. www.who.int/healthinfo/nationalburdenofdiseasemanual.pdf.
53. Murray C, Lopez A, eds. The global burden of disease: a comprehensive assessment ofmortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996.
54. Lahiri S, Levenstein C, Nelson DI, Rosenberg BJ. The cost effectiveness of occupational health interventions: prevention of silicosis. Am J Ind Med 2005;48:503-514 (Pubitemid 41746867)
55. WHO. The world health report 2002 - reducing risks, promoting healthy lives. Geneva: WHO, 2002. www.who.int/whr/2002/en/.
56. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500.
57. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44:1598-1606
58. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138:960-968 (Pubitemid 38129116)
59. De Wals P, Nguyen VH, Erickson LJ, Guay M, Drapeau J, St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004;22:1233-1240 (Pubitemid 38296667)
60. Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001;19:4204-4213 (Pubitemid 32703641)
61. Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009;25:161-170
62. Zahn M, Marshall GS. Clinical and epidemiological aspects of rotavirus infection. Pediatr Ann 2006;35:23-28 (Pubitemid 43139492)
63. CIA. The world factbook. Central Intelligence Agency, 2008. www.cia.gov/library/publications/the-world-factbook/index.html.
64. Public Information Bureau. Advance estimates of national income, 2007-2008. Government of India, February 7, 2008 (press release).
65. Indian National Information Centre. Union Budget 2007-2008. 2007. http://indiabudget.nic.in/ub2007-08/bag/bag4-2.pdf.
66. Madhavi Y. New combination vaccines: backdoor entry into India's universal immunization programme. Current Science 2006;90:1465-1469 (Pubitemid 43979418)
67. Jaffe S. New rotavirus vaccines on the horizon. Scientist 2005;19:37.
68. Kotecha P.Micronutrientmalnutrition in India: let us say no to it now. Indian J Community Med 2008;33:9-10.
69. India micronutrient national investment plan for 2007-2011 launched today. New Delhi: India PRWire, 2006. www.indiaprwire.com/pressrelease/health- care/20061019819.htm.
70. World Bank country classification table. Washington: World Bank, 2008. http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,, contentMDK: 20421402~pagePK:64133150~piPK:64133175~the-SitePK:239419,00.html
71. Georges-Courbot MC, Monges J, Siopathis MR, Roungou JB, Gresenguet G, Bellec L, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991;142:405-411
72. Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;1:1342-1345 (Pubitemid 17076248)
73. Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989;159:452-459 (Pubitemid 19065891)
74. Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996;174(suppl 1):S73-80. (Pubitemid 26293125)
75. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007;25:231-238 (Pubitemid 44856084)
76. Clemens JD, Stanton BF, Chakraborty J, Sack DA, Khan MR, Huda S, et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 1987;155:79-85. (Pubitemid 17225086)
77. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000;18:2399-2410
78. John TJ. Antibody response of infants in tropics to five doses of oral polio vaccine. BMJ 1976;i:812.
79. Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol 2004;2:473-482 (Pubitemid 39200014)
80. Patel AB, Dhande LA, Rawat MS. Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial. Cost Eff Resour Alloc 2003;1:7.